Abstract
The purpose of research. The study of the features of the left ventricle remodeling in the acutest stage of experimental myocardial infarction and the possibility of the correction of detected injuries. Methods. Experimental myocardial infarction in rats was induced by single-step ligation of the left descending coronary artery. The animals were randomized into 3 groups: 1st – sham-operated (n=6), 2nd – acute myocardial infarction (n=12) and 3d – doxycycline + acute myocardial infarction (n=9). Echocardiographic assessment of the dynamics of the alteration of left ventricle geometry was performed before and after opening the chest, and in 3, 10, 15, 20, 30, 45 and 60 minutes after coronary artery ligation. Results. The coronary artery ligation caused to pronounced changes in the geometry of the left ventricle, peaked to the 20th minute of ischemia. So, for example, the left ventricle end-systolic dimension (ESD) compared with the initial level increased from 1.90 to 3.80 mm (p<0,05), i.e. twofold; ejection fraction (EF) – decreased from 88,6 to 58,4% (p<0,05), i.e. by 34%; and fractional shortening (FS) declined from 52,6 to 26,5% (p<0,05), i.e. by 50%. In parallel with this there was noted the significant (p<0,05) increase of the end-diastolic volume (EDV) in average by 38%. In the following 40 minutes, there was observed some recovery of the cardiac pump function, which was stabilized to the 60th minute.The differences from the 20th minute of ischemia were statistically significant. In the group of animals treated with inhibitor of metalloproteinases 2 and 9 doxycycline (40 mg/kg, per os) for three days prior to coronary artery occlusion also caused reduction of the left ventricle systolic function, but in the first 20 minutes after beginning of ischemia the intensity of this process was less pronounced (the differences were significant). For example, at 20th minute of ischemia in the control animals ESD increased from 1.90 to 3.80 mm, i.e. by 2 times, while in the animals treated with doxycycline the increase in ESD accounted for 60% (from 1,79 to 2,98 mm respectively), the difference was significant (p=0,049). To this moment EF in control animals decreased from 88,6 to 58,4%, i.e. by 34%, while in the animals treated with doxycycline – only by 25% (or from 91,7 to 67,5%), the difference was significant (p=0,037). Conclusion. The results testify to the possibility of the use of inhibitors of metalloproteinases for the reduction of the intensity of early postinfarction remodeling of the left ventricle in the acutest phase of infarction, which not only helps to the maintenance of cardiac pumping function, but also reduces the risk of sudden cardiac death.
Keywords
Authors and affiliations
S.A. Kryzhanovskii, E.O. Ionova, V.N. Stolyaruk, I.B. Tsorin, M.B. Vititnova Research Zakusov Institute of Pharmacology, Baltiyskaya st., 8, Moscow, 125315, Russian Federation
References
Kitabayashi K., Siltanen A., Patila T. et al. Bcl-2 expression enhances myoblast sheet transplantation therapy for acute myocardial infarction. Cell. Transplant. 2010; 19 (5): 573–88.
Herrmann J.L., Abarbanell A.M., Wang Y, et al. Transforming growth factor-α enchances stem cell-mediated postischemic myocardial protection. Ann. Thorac. Surg. 2011; 92 (5): 1719–25.
Dayan A., Feinberg M.S., Holbova R. et al. Swimming exercise training prior to acute myocardial infarction attenuates left ventricular remodeling and improves left ventricular function in rats. Ann. Clin. Lab. Sci. 2005; 35 (1): 73–8.
Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function. Physiol. Rev. 2007; 87: 1285–342.
Judgutt B.I. Ischemia/infarction. Heart Fail. Clin. 2012; 8 (1): 43–51.
Vacek T.P., Metreveli N., Tyagi N., Vacek J.C., Pagni S., Tyagi S.C. Electrical stimulation of cardiomyocytes activates mitochondrial matrix metalloproteinase causing elecrtical remodeling. Biochem. Biophys. Res. Commun. 2011; 404 (3): 762–6.
Gallagher G.L., Jackson C.J., Hunyor S.N. Myocardial extracellular matrix remodeling in ischemic heart failure. Front. Biosci. 2007; 12: 1410–9.
Gasanov A.G., Bershova T.V. Rol` izmeneniy vnekletochnogo matriksa pri vozniknovenii serdechno-sosudistyh zabolevaniy. Biomed. himiya. 2009; 55 (2): 155–68. [Gasanov A.G., Bershova T.V. The role of changes of matrix metalloproteinase in cardiovascular diseases. Biomed Khim. 2009; 55 (2): 155–68 (in Russian)]
Shamhart P.E., Meszaros J.G. Non-fibrillar collagens: key mediators of post-infarction cardiac remodeling? J. Mol. Cell. Cardiol. 2010; 48 (3): 530–7.
Lang R.M., Bierig M., Devereux R.B. et al. Recomendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Camber Quantification Writing Group, developed in conjunction with European Association of Echocardiography, a branch of the European Society of Cardiology. J. Am. Soc. Echocardiogr. 2005; 18: 1440–63.
Martinez P.F., Okoshi K., Zornoff L.A.M., Oliveira S.A., Campos D.H., Lima A.R., Damatto R.L., Cezar M.D., Bonomo C., Guizoni D.M., Padovani C.R., Cicogna A.C., Okoshi M.P. Echocardiographic detection of congestive heart failure in postinfarction rats. J. Appl. Physiol. 2011; 111 (2): 543–51.
Sun S., Wang X., Qu X., Li Y., Yu Y., Song Y., Wang S.J. Increased expression of myocardial semaphorin 3A in isoproterenol-induced heart failure rats. Chin. Med. J. 2011; 124 (14): 2173–8.
Kryzhanovskiy S.A., Ionova E.O., Stolyaruk V.N., Corin I.B., Vititnova M.B. Vozmozhnost` ispol`zovaniya e`hokardiografii dlya izucheniya postinfarktnogo remodelirovaniya serdca u melkih zhivotnyh. Innovacii v sovremennoy farmakologii. M.: Folium, 102.[Kryzhanovskii S.A., Ionova E.O., Stolyaruk V.N., Tsorin I.B., Vititnova M.B. The ability of the echocardiography use to study postinfarction cardiac remodeling in small animals. Innovations in modern pharmacology. M.: Folium, 102 (in Russian)]
Abbate A., Narula J. Role of apoptosis in adverse ventricular remodeling. Heart Fail. Clin. 2012; 8 (1): 79–86.
Seropian I.M., Toldo S., Van Tassel B.W., Abbate A. Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. J. Am. Coll. Cardiol. 2014; 63 (16): 1593–603.
Saridakis N.S., Toumanidis S.T., Vintzileou A.M. et al. Effect of dobutamine on left ventricular functional geometry after acute myocardial infarction: experimental study. Hellenic J. Cardiol. (HJC). 2007; 48: 72–9.
Campbell R.W.F., Murray A., Julian D.G. Ventricular arrhythmias in first 12 hours of acute myocardial infarction. Natural history study. Br. Heart J. 1981; 46: 351–7.
Zipes D.P., Camm A.J., Borggrefe M. et al. ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to develop Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death). Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J. Am. Coll. Cardiol. 2006; 48: 247–346.
Pokorný J., Staněk V., Vrána M. Sudden cardiac death thirty years ago and at present. The role of autonomic disturbaces in acute myocardial infarction revisited. Physiol. Res. 2001; 60 (5): 715–28.
Falk E., Nakano M., Bentzon J.F., Finn A.V., Virmani R. Update on acute coronary syndromes: the pathologists’ view. Eur. Heart. J. 2013; 34 (10): 719–28.
Kuller L.H., Cooper M., Perper J., Fisher R. Myocardial infarction and sudden death in an urban community. Bull. N.Y. Acad. Med. 1973; 49 (6): 532–43.
Hearse D.J., Ferrari R., Sutherland F.J. Cardioprotection: Intermittent ventricular fibrillation and rapid pacing can induce preconditioning in the blood-perfused rat heart. J. Mol. Cell. Cardiol. 1999; 31 (11): 1961–73.
Yan G.X., Joshi A., Guo D. et al. Phase 2 reentry as a trigger to initiate ventricular fibrillation during early acute myocardial ischemia. Circulation. 2004; 110 (9): 1036–41.
Štengl M. Experimental models of spontaneous ventricular arrhythmias and of sudden cardiac death. Physiol. Res. 2010; 59 (1): 25–31.
Curtis M.J. Characterisation, utilisation and clinical relevance of isolated perfused heart models of ischemia-induced ventricular fibrillation. Cardiovasc. Res. 1998; 39: 194–215.
Swann M.H., Nakagawa H., Vanoli E. et al. Heterogeneous regional endocardial repolarization is associated with increased risk for ischemia-dependent ventricular fibrillation after myocardial infarction. J. Cardiovasc. Electrophysiol. 2003; 14 (8): 873–9.
Takahashi T., van Dessel P., Lopshire J.C. et al. Optical mapping of the functional reentrant circuit of ventricular tachycardia in acute myocardial infarction. Heart Rhythm. 2004; 1 (4): 451–9.
Crisu D. Sudden death and ventricular arrhythmias risk stratification after myocardial infarction. Rev. Med. Chir. Soc. Med. Nat. Iasi. 2010;114 (1): 13–9.
Myerburg R.J., Junttila M.J. Sudden cardiac death. Sudden cardiac death caused by coronary heart disease. Circulation. 2012; 125: 1043–52.
Rudic B., Veltmann C., Kuntz E. et al. Early repolarization pattern is associated with ventricular fibrillation in patients with acute myocardial infarction. Heart Rhythm. 2012; 9 (8): 1295–300.
Chung S.S. Early identification of risk factors for sudden cardiac death. Nat. Rev. Cardiol. 2010; 7 (6): 318–26.
El-Sherif N., Khan A., Savarese J., Turitto G. Pathophysiology, risk stratification, and management of sudden cardiac death in coronary artery disease. Cardiology J. 2010;17 (1): 4–10.
Santangeli P., Dello Russo A., Casella M. et al. Left ventricular ejection fraction for the risk stratification of sudden cardiac death: friend or foe? Internal. Med. J. 2011; 41: 55–60.
Clements-Jewery H., Hearse D.J., Curtis M.J. Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation. British J. Pharmacol. 2005; 145 (5): 551–64.
de Groot J.R., Coronel R. Acute ischemia-induced gap junctional uncoupling and arrhythmogenesis. Cardiovasc. Res. 2004; 62: 323–34.
Ali M.A., Fan X., Schulz R. Cardiac sarcomeric proteins: novel intracellular targets of matrix metalloproteinase-2 in heart disease. Trends Cardiovasc. Med. 2011; 21 (4):112–8.
Halade G.V., Jin Y.F., Lindsey M.L. Matrix metalloproteinas (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol. Ther. 2013; 139 (1): 32–40.
Hughes B.G., Schulz R. Targeting MMP-2 to treat ischemic heart injury. Basic Res. Cardiol. 2014; 109 (4): 424.
Kandasamy A.D., Chow A.K., Ali M.A., Schulz R. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc. Res. 2010; 85 (3): 413–23.
Hughes B.G., Fan X., Cho W.J., Schulz R. MMP-2 is localized to the mitochondria-associated membrane of the heart. Am. J. Physiol. Heart Circ. Physiol. 2014; 306 (5): 764–70.
Bench T.J., Jeremias A., Brown D.L. Matrix metalloproteinase inhinbiton with tetracyclines for the treatment of coronary artery disease. Pharmacological Research. 2011; 64: 561–6.
Griffin M.O., Fricovsky E., Ceballos G., Villarreal F. Tetracyclines: a pleotropic family of compounds with promising therapeutic properties. Review of the literature. Am. J. Physiol. Cell. Physiol. 2010; 299: 539–48.
Fana X.Z., Zhu H.J., Wu X., Yan J., Xu J., Wang D.G. Effects of doxycycline on cx43 distribution and cardiac arrhythmia susceptibility of rats after myocardial infarction. Iran. J. Pharm. Res. 2014; 13 (2): 613–21.